Byrne Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
AIM
FWIA
DLA
ETC
Byrne Asset Management's BMY Position: Q2 2026 in Review
Byrne Asset Management reduced its Bristol-Myers Squibb (BMY) stake by 3.4% in Q2 2026, selling an estimated $3.67K and leaving 1,819 shares worth $105K. The position accounts for 0.06% of the portfolio, ranked #240.
Byrne Asset Management first reported a position in BMY in Q4 2021 and has held it in 19 quarters since. The position peaked at $427K in Q2 2022. 878 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Byrne Asset Management held 1,819 shares of Bristol-Myers Squibb worth $105K as of Q2 2026.
- Byrne Asset Management sold 64 Bristol-Myers Squibb shares in Q2 2026, an estimated $3.67K.
- Bristol-Myers Squibb made up 0.06% of Byrne Asset Management's portfolio in Q2 2026, its #240 holding.
- Byrne Asset Management first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 19 quarters since.
- Byrne Asset Management's Bristol-Myers Squibb position peaked at $427K in Q2 2022.
- 878 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Byrne Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.